* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6535 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lumosa Therapeutics Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co (ROCO:6535) has a Days Payable of 10.75 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lumosa Therapeutics Co and its competitors. This is 89% below median its historical median of 99.92. Over the past decade, Lumosa Therapeutics Co's Days Payable has ranged from 23.85 to 354.84. According to the industry distribution chart, Lumosa Therapeutics Co ranks #602 out of 700 companies in the Biotechnology industry, placing it in the top 86%.
Is Lumosa Therapeutics Co's Days Payable too high?
Lumosa Therapeutics Co's current Days Payable of 10.75 is 89% below median its 10-year median of 99.92. Over the past 10 years, this metric has ranged from a low of 23.85 to a high of 354.84. The Biotechnology industry median Days Payable is 113.10. Lumosa Therapeutics Co's value of 10.75 is 90.5% below this industry median. Based on the distribution chart, Lumosa Therapeutics Co ranks #602 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lumosa Therapeutics Co ranks #602 out of 700 companies for Days Payable. This places Lumosa Therapeutics Co in the lower half of its industry. The industry median Days Payable is 113.10. Lumosa Therapeutics Co's value of 10.75 is 90.5% below this benchmark. Historically, Lumosa Therapeutics Co's own Days Payable has ranged from 23.85 to 354.84 over the past decade. While the company's 10-year median is 99.92 vs. the industry median of 113.10, Lumosa Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumosa Therapeutics Co's current Days Payable of 10.75 is 90.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lumosa Therapeutics Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumosa Therapeutics Co's current Days Payable is 10.75, which is 89% below median its own 10-year median of 99.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$131.03, compared to a current price of NT$106.50 — trading 18.7% below its estimated fair value. The current Days Payable is 10.75, which is 89% below median its 10-year median of 99.92 and 90.5% below the Biotechnology industry median of 113.10. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Days Payable is 10.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$106.50 is trading 18.7% below its estimated GF Value™ of NT$131.03.
GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.
Key valuation signals for ROCO:6535:
Days Payable: 10.75 (89% below median its 10-year median of 99.92)
GF Value™: NT$131.03 vs. price of NT$106.50 (18.7% below fair value)
Industry Position: 90.5% below the Biotechnology median (#602 of 700)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score
Get the complete analysis for ROCO:6535
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
